Interferon

A clinical trial is underway to assess the safety of a novel immunotherapy combination for the treatment of mild to moderate COVID-19 infection among patients with cancer.

Treatment with IV recombinant human interferon beta-1a failed to improve outcomes in mechanically ventilated patients with moderate or severe acute respiratory distress syndrome, according to data published in JAMA.

In this video, Jeanne M. Palmer, MD, hematologist and oncologist at the Mayo Clinic, discussed recent FDA approvals in the field.